Disclaimer: Consult with a doctor before deciding on a treatment plan for cancer or any other disease.
Treatment with intravenous curcumin has shown promise in treating several different types of cancer, in particular colon cancer, multiple myeloma, breast cancer, melanoma, and pancreatic cancer especially when used as part of a cancer protocol. A large number of diseases are positively affected by intravenous curcumin treatment.
Curcumin is a component of the spice turmeric (Curcuma longa). It’s effects on the body been extensively researched over the past 25 years demonstrating that it has the ability to modulate cell signaling pathways. Promising effects have been demonstrated in a variety of diseases including :
- Cardiovascular disease
- Ulcerative Proctitis
- Crohn’s disease
- Ulcerative colitis
- Irritable Bowel Syndrome
- Tropical Pancreatitis
- Gastric and peptic ulcers
- Idiopathic orbital inflammatory pseudotumor
- Oral lichen planus
- Gastric inflammation
- Lupus nephritis
- Acute coronary syndrome
- Diabetic neuropathy
- Diabetic microangiopathy
- Renal conditions
- Biliary dyskinesia
- Djerine-Sottas disease
- Chronic bacterial prostatitis
- Liver conditions
- Chronic arsenic exposure
- Alcohol intoxication 
When consumed by mouth, the bioavailability of curcumin is low , but when administered via IV, the bioavailability is much higher.
Colorectal cancer is the second leading cause of cancer deaths in the United States. Treatment options other than surgical resection at an early stage in the disease plus chemotherapy have been the mainstay for quite some time, but curcumin has shown potential as a colorectal cancer treatment in numerous trials. According to a recent study, patient with colorectal cancer who were given curcumin (360 mg in a capsule form for 10 to 30 days) prior to surgery, increased body weight and increased the number of apoptotic cells .
Globally, pancreatic cancer is the 4th most common cause of death from cancer . Studies have shown that curcumin is well-tolerated in patients with advanced pancreatic cancer. One patient in a study that included 21 patients, showed significant tumor regression and increases in serum cytokine levels in response to treatment with curcumin .
Several studies have shown that curcumin has potential against multiple myeloma .
Curcumin has also been shown to selectively induce apoptosis and inhibit the growth of melanoma cells while leaving normal, healthy melanocytes intact .
Turmeric has been used effectively to protect patients against cancerous lesions in various parts of the body.
Curcumin is an adjuvant therapy for cancer. It is generally used in combination with other treatment options such as chemotherapy agents which mean that it doesn’t pose a threat to conventional medicine. As such, curcumin treatment is more accessible to patients using conventional medicine to cure cancer.
Safety and Effectiveness
Research has shown that curcumin is safe up to a dose of 12 grams per day over the course of 3 months . One study showed that in combination with gemcitabine (Gemzar – a chemotherapy agent), curcumin was well-tolerated at up to 8 grams/day in patients with pancreatic cancer . Another study demonstrated that up to 8 grams of curcumin per day was safe to use in patients with pancreatic cancer .
How Intravenous Curcumin Is Administered
Intravenous curcumin is administered alone or in tandem with other treatments. It has been used in the treatment of breast cancer with research recommending the administration of curcumin at 6 grams/day for seven consecutive days every 3 weeks .
Possible Negative Effects
Curcumin is generally well-tolerated up to a dose of 8 grams/day .
Other Important Information
As an adjuvant therapy, curcumin can help cancer patients lower inflammation and boost their immune systems. Intravenous curcumin is a helper therapy that should be used in combination with other cancer treatment strategies.
 Subash, C. G., Sridevi P., Bharat, B. A. (2012).Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials. Retrieved March 19, 2018 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535097/
 Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R., Srinivas, P. S. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Retrieved March 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/9619120
 Bayet-Robert, M., Kwiatkowski, F., Leheurteur, M. Gachon, F., Planchat, E., Abrial, C. et al. (2010). Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Retrieved March 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/19901561
 Kanai, M., Yoshimura, K., Asada, M., Imaizumi, A., Suzuki, C., Matsumoto, S., et al. (2011). A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Retrieved March 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/20859741
 Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Retrieved March 19, 2019 from https://www.ncbi.nlm.nih.gov/pubmed/18628464
 Hariharan, D., Saied, A., Kocher, H. M. (2008). Analysis of mortality rates for pancreatic cancer across the world. Retrieved March 19, 2018 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504856/
 Vadhan-Raj, S., Weber, D., Wang, M., Giralt, S., Alexanian, R., Thomas, S., et al. (2007). Curcumin downregulates NF-KappaB and related genes in patients with multiple myeloma: results of a phase ½ study. Blood. 110(11): 357a.
 Marin, Y. E., Wall, B. A., Wang, S., Namkoong, J., Martino, J. J., Suh, J., Lee, H. J., Rabson, A. B., Yang, C. S., Chen S., Ryu, J. H. (2007). Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Retrieved March 19, 2018 from https://www.ncbi.nlm.nih.gov/pubmed/17885582